Clear Cell Adenocarcinoma

Subscribe to Selected New Research on Clear Cell Adenocarcinoma

195 relevant articles (5 outcomes, 20 trials/studies) found for this Disease

Description: An adenocarcinoma characterized by the presence of varying combinations of clear and hobnail-shaped tumor cells. There are three predominant patterns described as tubulocystic, solid, and papillary. These tumors, usually located in the female reproductive organs, have been seen more frequently in young women since 1970 as a result of the association with intrauterine exposure to diethylstilbestrol. (From Holland et al., Cancer Medicine, 3d ed)

Also Known As:

Adenocarcinoma, Clear Cell; Adenocarcinomas, Clear Cell; Cell Adenocarcinoma, Clear; Cell Adenocarcinomas, Clear; Clear Cell Adenocarcinomas

Relationship Network

Disease Context: Research Results

Neoplasms: 387640

Neoplasms by Histologic Type: 1

Glandular and Epithelial Neoplasms: 238

Carcinoma: 89421

Adenocarcinoma: 25851

Clear Cell Adenocarcinoma: 195

Related Diseases

1.	Neoplasms (Cancer)
2.	Carcinoma (Carcinomatosis)
3.	Ovarian Neoplasms (Ovarian Cancer)
4.	Endodermal Sinus Tumor (Endodermal Sinus Tumors)
5.	Ectropion

Experts

1.	Aoki, Daisuke: 5 articles (03/2008 - 09/2004)
2.	Susumu, Nobuyuki: 5 articles (03/2008 - 09/2004)
3.	Suzuki, Nao: 4 articles (03/2008 - 09/2004)
4.	Higashiguchi, Atsushi: 3 articles (03/2008 - 09/2005)
5.	Ezawa, Sachiko: 3 articles (03/2008 - 09/2004)
6.	Suzuki, Atsushi: 3 articles (03/2007 - 09/2004)
7.	Hosoi, Fumihito: 2 articles (03/2008 - 09/2004)
8.	Kitazato, Kenji: 2 articles (03/2008 - 09/2004)
9.	Minami, Sawako: 2 articles (08/2006 - 02/2006)
10.	Yamoto, Mareo: 2 articles (08/2006 - 02/2006)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Clear Cell Adenocarcinoma:

1.	Cisplatin (Platino)FDA LinkGeneric 12/01/2008 - "Since GPX3 suppression increased the cisplatin sensitivity of clear cell adenocarcinoma cells, GPX3 may be a candidate gene associated with the low cisplatin sensitivity of clear cell adenocarcinoma." 12/01/2008 - "GPX3 suppression by RNA interference increased cisplatin sensitivity 3.3-4.2-fold in 3 of the 4 clear cell adenocarcinoma cell lines" 12/01/2008 - "Obtained candidate genes were suppressed by RNA interference and changes in the cisplatin sensitivity of clear cell adenocarcinoma cells were observed" 09/01/1999 - "Remarkable suppressive effect of consecutive low-dose cisplatin therapy on advanced ovarian clear cell adenocarcinoma." 05/01/1989 - "A 60-year-old woman with recurrent stage II endometrial cancer (clear cell adenocarcinoma) was treated with combination chemotherapy containing cisplatin (CDDP)" Order ALL the reference details at left...
2.	irinotecan (Camptosar)FDA LinkGeneric 06/01/2005 - "OBJECTIVE: The purpose of this study was to report the results of adjuvant CPT-11 and MMC combination chemotherapy (CPT-M) for ovarian clear cell adenocarcinoma (OCCA)" 09/01/1999 - "CONCLUSION: CPT-11 plus cisplatin is feasible and has efficacy for ovarian clear cell adenocarcinoma" 09/01/1999 - "We planned a pilot study of CPT-11 and cisplatin for the treatment of ovarian clear cell adenocarcinoma" 09/01/1999 - "A pilot study of CPT-11 and cisplatin for ovarian clear cell adenocarcinoma." 04/01/1996 - "Successful treatment of clear cell adenocarcinoma of the ovary (OCCA) with a combination of CPT-11 and mitomycin C]" Order ALL the reference details at left...
3.	Doxorubicin (Adriamycin)FDA LinkGeneric 07/01/2007 - "Our results suggest that adriamycin-related chemicals that are taken up via SLC22A16 may have the potential to be effective against clear-cell adenocarcinoma." 07/01/2001 - "RESULTS: In the 19 ovarian carcinomas examined, the mean Topo II alpha index (%) and the tumor cell growth inhibition rate (I.R.: %) for doxorubicin and etoposide in the clear cell adenocarcinomas [15.8, 21.4, 32.3] were all lower than in the endometrioid [33.9; p<0.001, 58.3, 61.9; p<0.05, respectively] and serous adenocarcinomas [43.6; p<0.001, 75.0, 79.8; p<0.01, respectively]" Order ALL the reference details at left...
4.	TAC 101IBA 09/01/2004 - "RESULTS: Apoptosis occurred in all of the cell lines (except KF) in a concentration-dependent manner after exposure to TAC-101 and was markedly induced in RMG-I and RMG-II cells (derived from ovarian clear cell adenocarcinomas)" 09/01/2004 - "CONCLUSION: Oral TAC-101 shows potential as a novel antitumor agent for ovarian carcinoma, especially ovarian clear cell adenocarcinoma." 03/01/2008 - "CONCLUSION: These in vitro findings suggest that a combination of TAC-101 and cisplatin may be a potential new treatment for ovarian clear cell adenocarcinoma." 03/01/2008 - "TAC-101 (8 mg/kg/day orally for 21 days), cisplatin (7 mg/kg intravenously on day 1), or a combination of both drugs at the same dosages was administered to nude mice implanted subcutaneously with RMG-I or RMG-II clear cell adenocarcinoma cells" 03/01/2008 - "OBJECTIVE: A novel retinoid, TAC-101 (4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid), induces apoptosis of ovarian clear cell adenocarcinoma" Order ALL the reference details at left...
5.	trastuzumab (Herceptin)FDA Link 11/01/2002 - "HER2 is frequently over-expressed in ovarian clear cell adenocarcinoma: possible novel treatment modality using recombinant monoclonal antibody against HER2, trastuzumab." Order ALL the reference details at left...
6.	Diethylstilbestrol (Stilbestrol)FDA Link 06/01/1997 - "BACKGROUND: The objective of this study was to update the registry of women in the Netherlands with clear cell adenocarcinoma (CCAC) of the cervix or vagina with or without intrauterine exposure to diethylstilbestrol (DES)" 03/01/1981 - "Studies have shown a possible relationship between perinatal exposure to DES(diethylstilbestrol) and clear cell adenocarcinoma of the vagina and cervix in young women" 04/01/2007 - "BACKGROUND: Primary vaginal clear cell adenocarcinoma (CCA) is a rare gynecological malignancy occurring predominantly in young females with a history of diethylstilbestrol exposure in utero" 04/01/2007 - "Diethylstilbestrol (DES)-induced clear cell adenocarcinoma of the vagina metastasizing to the brain." 11/01/2005 - "Clear cell adenocarcinoma of the cervix in a child without in utero exposure to diethylstilbestrol: a case report and review of the literature." Order ALL the reference details at left...
7.	DNA (Deoxyribonucleic Acid)IBA 04/01/1983 - "A study was performed to determine if ploidy levels of nuclear DNA content could be used as a prognostic index of the biologic behavior of clear cell adenocarcinoma of the vagina and cervix in young females" 03/15/1973 - "Studies of nuclear DNA in vaginal adenosis and clear-cell adenocarcinoma." 04/01/1983 - "Nuclear DNA content of clear cell adenocarcinoma of the vagina and cervix and its relationship to prognosis." 12/01/2008 - "Exhaustive gene profiling of 4 ovarian clear cell adenocarcinoma cell lines, KK, OVMANA, OVSAYO, and RMG-1 and 4 ovarian serous adenocarcinoma cell lines, KF, HRA, SHIN-3 and KOC-2S was performed by DNA microarray" 09/01/2006 - "Mean DNA index of the stemline in serous adenocarcinoma (1.72) and clear cell adenocarcinoma (1.81) was higher than in endometrioid adenocarcinoma (1.1)" Order ALL the reference details at left...
8.	Hepatocyte Nuclear Factor 1-betaIBA 07/01/2007 - "Recent studies have noted specific expression of hepatocyte nuclear factor (HNF) 1beta in ovarian clear-cell adenocarcinoma (CCA)" 07/01/2007 - "Immunohistochemical detection of hepatocyte nuclear factor 1beta in ovarian and endometrial clear-cell adenocarcinomas and nonneoplastic endometrium." 03/01/2007 - "Specific expression of hepatocyte nuclear factor-1beta in the ovarian clear cell adenocarcinoma and its application to cytological diagnosis." 03/01/2007 - "Previous studies using DNA microarrays have demonstrated that hepatocyte nuclear factor-1beta (HNF-1beta) is expressed specifically in clear cell adenocarcinoma (CCC)" Order ALL the reference details at left...
9.	ParaffinIBA 09/01/1998 - "METHODS: Twenty-one paraffin-embedded clear cell adenocarcinomas were immunohistochemically stained for bcl-2 (antibody M 887, Dako, Carpinteria, CA) and DNA fragmentation (ApopTag, Oncor, Gaithersburg, MD), a marker for apoptosis" 03/01/1996 - "METHODS: Paraffin-embedded tissue specimens from 21 women (median age 22 years) with clear cell adenocarcinoma of the vagina or cervix were studied" 09/01/1994 - "METHODS: Paraffin-embedded tissue specimens were studied from 14 women with clear-cell adenocarcinoma of the vagina or cervix" 10/01/1996 - "The paraffin-embedded sections from eight cases of ovarian clear cell adenocarcinoma were immunostained with monoclonal antibody MIB1 using microwave oven heating for antigen retrieval" 01/01/1996 - "The tissues were from normal proliferative endometrium (formalin-fixed paraffin-embedded) material and clear-cell adenocarcinoma of the ovary (formalin-fixed paraffin-embedded and frozen material)" Order ALL the reference details at left...
10.	Estrogens (Estrogen)FDA Link 05/01/1979 - "The importance of the mouse model for the study of the relevance of estrogen-induced, irreversible changes and other factors in the development of human clear cell adenocarcinomas in the vagina and cervix is stressed." 02/01/1976 - "However, a similar sequence of events must also be accepted to occur "spontaneously" since clear cell adenocarcinoma can develop in women without a history of maternal estrogens." 04/01/1998 - "Prenatal exposure to DES has been associated with several malformations in the lower genital tract, a higher prevalence of adenosis, and increased risk of clear cell adenocarcinoma, and estrogen-dependent tumors" 09/01/2006 - "OBJECTIVE: To investigate the involvement of estrogen receptor (ER) beta in the proliferation of ovarian clear cell adenocarcinoma by restoring ERbeta expression in a cell line ES-2" 05/15/2004 - "Food and Drug Administration issued a warning about the use of diethylstilbestrol during pregnancy after a relationship between exposure to this synthetic estrogen and the development of clear cell adenocarcinoma of the vagina and cervix was found in young women whose mothers had taken diethylstilbestrol while they were pregnant" Order ALL the reference details at left...

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 08/01/1997 - "Efficacy of chemotherapy for clear cell adenocarcinoma of the ovary]" 05/01/2008 - "A combination of chemoirradiation and chemotherapy for treatment of advanced clear cell adenocarcinoma of the cervix." 12/01/2002 - "Complete response to radiation therapy in a patient with chemotherapy-resistant ovarian clear cell adenocarcinoma." 08/01/1997 - "Therefore, high-dose EP therapy might be an effective chemotherapy for some patients with ovarian clear cell adenocarcinoma." 07/01/2006 - "Mucinous and clear cell adenocarcinomas are the major histological types of ovarian epithelial cancer and are associated with a poor prognosis due to their resistance to chemotherapy" Order ALL the reference details at left...
2.	Combination Drug Therapy (Combination Chemotherapy) 10/01/2006 - "Colonic perforation in a patient treated with combination chemotherapy for recurrent ovarian clear cell adenocarcinoma]" 10/01/2005 - "PURPOSE: Patients with ovarian clear cell adenocarcinoma generally have a poor response to combination chemotherapy and have overall poorer prognosis than patients with other histologic types of ovarian cancer" 11/01/1994 - "Clear cell adenocarcinoma of the vagina in a young female, treated by combination chemotherapy (local and systemic chemotherapy), complicated with chromosomal abnormality." 06/01/2005 - "OBJECTIVE: The purpose of this study was to report the results of adjuvant CPT-11 and MMC combination chemotherapy (CPT-M) for ovarian clear cell adenocarcinoma (OCCA)" 01/01/2000 - "Successful treatment of a patient with recurrent ovarian clear cell adenocarcinoma under combination chemotherapy of 5-FU (civ) and low-dose CDDP (i.v.)]" Order ALL the reference details at left...
3.	Brachytherapy 03/01/1998 - "The prognosis is not as good for patients treated for a clear cell adenocarcinoma of the vagina and/or the cervix who may have morphological and/ or functional anomalies of the genital tract, following exposure to diethylstilboestrol and brachytherapy (group 1)" 11/01/1996 - "Twelve magnetic resonance (MR) imaging studies were performed during intracavitary brachytherapy (10 initial studies and two during repeat brachytherapy) in 10 patients with clear cell adenocarcinoma (n = 9) or epithelioma (n = 1)" 09/01/1989 - "Treatment policy included initial exploratory laparotomy with lymph node biopsy and ovarian transposition, chemotherapy (except in clear cell adenocarcinoma) and/or external radiotherapy prior to interstitial brachytherapy" 09/01/1989 - "Actuarial 5-year local control is 84%, but including salvage is 94%: three (two rhabdomyosarcoma, one clear cell adenocarcinoma) of the five local failures were salvaged by surgery, chemotherapy and/or brachytherapy" Order ALL the reference details at left...
4.	Nephrectomy 01/01/2008 - "In 1992 he underwent left side radical nephrectomy with histopathological diagnosis of clear cell adenocarcinoma" 06/01/1993 - "We report the case of a patient who underwent a left nephrectomy for clear cell adenocarcinoma" 01/01/2008 - "METHODS: We present the case of a 60-year-old male patient with the diagnosis of inferior maxillary skin metastasis 18 months after radical nephrectomy for clear cell adenocarcinoma" 04/01/2005 - "METHODS/RESULTS: We report the case of a 65-year-old male with a cutaneous metastasis in the root of his inferior left extremity one year after right nephrectomy for a clear cell adenocarcinoma" 08/01/1984 - "High local recurrence rates were found in cases of transitional cell carcinoma with whole wall involvement or extension to adjacent tissues (4 of 8 patients, 50 per cent), clear cell adenocarcinoma with lymph node involvement (3 of 7 patients, 43 per cent) and partial nephrectomy (3 of 6 patients, 50 per cent)" Order ALL the reference details at left...
5.	Hysterectomy 11/01/1993 - "The third patient underwent radical hysterectomy, bilateral pelvic lymphadenectomy, and total vaginectomy for clear cell adenocarcinoma of the cervix that also involved two-thirds of the vagina" 11/01/1993 - "The second patient with clear cell adenocarcinoma of the vagina developed recurrent disease at the apex of the vagina 5 years after radical hysterectomy, bilateral pelvic lymphadenectomy, and partial vaginectomy" 11/01/1998 - "The main indications for laparoscopic ovarian transposition are a patient with a small invasive cervical carcinoma (<2 cm) in a patient <40 years of age who is treated by initial laparoscopically assisted vaginal radical hysterectomy and a patient with a clear cell adenocarcinoma of the cervix and upper vagina." 01/01/1998 - "A patient with an endometrial clear cell adenocarcinoma confined to a polyp developed recurrent disease in the abdomen and pelvis four years following hysterectomy" 01/01/1995 - "CASE REPORT: A 63 year old female had a total abdominal hysterectomy, bilateral salpingo-oophorectomy, pelvic and paraaortic lymphadenectomy, partial omentectomy, and a staging procedure which achieved optimal debulking of a clear cell adenocarcinoma of the ovary" Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Clear Cell Adenocarcinoma

*WARNING* This specific disease subtype has a relatively small number of significant evidence outcomes. You may proceed to order anyway, or go back to the search field and enter a more general type of the target illness. Once your report has been ordered, however, we can't refund the purchase.

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 5 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>